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ABSTRACT
Oncogene activation is an established driver of tumorigenesis. An apparently 
inevitable consequence of oncogene activation is the generation of DNA replication 
stress (RS), a feature common to most cancer cells. RS, in turn, is a causal factor in 
the development of chromosome instability (CIN), a near universal feature of solid 
tumors. It is likely that CIN and RS are mutually reinforcing drivers that not only 
accelerate tumorigenesis, but also permit cancer cells to adapt to diverse and hostile 
environments. This article reviews the genetic changes present in cancer cells that 
influence oncogene-induced RS and CIN, with a particular emphasis on regions of 
the human genome that show enhanced sensitivity to the destabilizing effects of RS, 
such as common fragile sites. Because RS exists in a wide range of cancer types, we 
propose that the proteins involved counteracting this stress are potential biomarkers 
for indicating the degree of RS in cancer specimens. To test this hypothesis, we 
conducted a pilot study to validate whether some of proteins that are known from 
in vitro studies to play an essential role in the RS pathway could be suitable as a 
biomarker. Our results indicated that this is possible. With this review and pilot study, 
we aim to accelerate the development of a biomarker for analysis of RS in tumor 
biopsy specimens, which could ultimately help to stratify patients for different forms 
of therapy such as the RS inhibitors already undergoing clinical trials.
INTRODUCTION
Despite huge advances in our understanding of 
basic cancer biology, the incidence of cancer worldwide 
is still rising, and the overall survival rates for patients 
with advanced cancer are still low. For example, a World 
Health Organization report in 2012 revealed that there 
were approximately 14 million newly recorded cases 
of cancer worldwide that year, as well as over 8 million 
cancer-related deaths [1]. Four years on from this report, 
the same general picture remains, with a particularly 
negative outlook existing for advanced cancers. Taking 
colon cancer cases recorded during 2014-2015 in the USA 
as an example, those patients with early stage disease 
(Stage I) had a greater than 90% chance of surviving for 
more than 5 years after diagnosis. Unfortunately, however, 
only around 40% of cases are diagnosed at such an early 
disease stage. In those cases where the cancer had spread 
to distant organs (stage IV patient), the 5-year survival 
dropped dramatically to only around 15%. The five-year 
survival rate for all colon cancer is currently around 65% 
[2]. Clearly, to significantly improve the survival of cancer 
patients, progress must be made in targeting those cancers 
that are at an advanced stage at the point of diagnosis. 
Cancer cells differ from most normal cells in that 
they display an unlimited capacity for proliferation. 
This altered proliferative capacity is a consequence 
of the effects of genetic changes that arise during 
tumorigenesis, which are generally acquired as part of a 
sequential, multi-step process. Somewhat ironically, the 
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same mutation-selection evolutionary law that Darwin 
described for the development of different species shapes 
this pathological ‘evolutionary’ process. In the case of 
cancer development, the mutations are either inherited, 
or more frequently acquired somatically. Recent cancer 
genome sequencing efforts have revealed a bewildering 
array of different mutations in many of the most common 
cancers. Nevertheless, in many cases, there appears to 
be a common set of genes mutated characteristically in a 
particular tumor type. Cells carrying these genetic changes 
are then subjected to powerful selection imposed by the 
environment in which the cell resides. As a result, cancers 
often ‘evolve’ differently in different organs and even in 
the same organ from different patients. Moreover, their 
ability to invade surrounding tissue, as well as to spread 
to and survive within distant organs, can be very different. 
This genetic and phenotypic diversity has imposed huge 
challenges for the development of curative therapies 
because ‘one size clearly does not fit all’ when it comes to 
selection of the appropriate treatment options. 
It is well established that cancers arise primarily as 
a result of a series of changes to two classes of genes: 
oncogenes and tumor suppressor genes. These changes 
result either in the activation of the oncogene or in the 
inactivation of the tumor suppressor gene, and are often 
termed ‘driver mutations’. For example, approximately 
15 different driver mutations (as well as >60 ‘passenger’ 
mutations that are not directly involved in tumorigenesis) 
have been found in colon cancers [3]. When oncogenes 
become activated, one of the main consequences is the 
development of so-called ‘DNA replication stress’ (RS). 
While RS lacks a clear universal definition, it is usually 
taken to mean a situation in which DNA replication 
forks are disrupted leading to DNA damage and/or the 
accumulation of single stranded DNA. This leads to a 
DNA damage checkpoint response associated with the 
activation of the ATR and CHK1 kinases. If this disruption 
to replication is not dealt with promptly or appropriately, 
RS can lead to detrimental consequences including 
chromosome translocations or whole chromosome 
missegregation during mitosis leading to aneuploidy. 
Although initially considered a rare event associated 
only with a limited set of oncogenes, recent research has 
revealed that RS is triggered by the activation of a wide 
range of oncogenes, including many of the most common 
cancer-associated events such as c-Myc amplification, 
mutation of Ras, and overexpression of Cyclin D or the 
replication licensing factors Cdt1 and Cdc6 [4, 5]. 
There is a large body of evidence to indicate that 
chromosomal instability (CIN) in cancer cells is a driving 
force during tumorigenesis, and one of the major causes 
not only of heterogeneity in cancer cells, but also of cancer 
cell resistance to radiotherapy and chemotherapy [6]. As 
alluded to above, it has been proposed that RS plays a 
central role in the generation of structural and numerical 
CIN [7]. Indeed, it is conceivable that CIN and RS are 
mutually reinforcing drivers that permit cancer cells to 
have a selective advantage when adapting to a challenging 
environments. This raises the question of whether we 
can define a common molecular pathway or process that 
exists in many, if not all, cancers, that would allow us 
to identify a useful cancer biomarker? This article will 
focus on the genetic changes present in cancer cells that 
influence oncogene-induced RS and CIN, with a particular 
emphasis on common fragile sites (CFSs) in the human 
genome because of an accumulating body of evidence 
indicating that these loci are major hotspots for cancer-
associated genome rearrangements due to their exquisite 
sensitivity to RS. We will also present pilot data pertaining 
to the identification of potential markers of RS in cancer 
biopsies. Ultimately, such a marker would help to stratify 
patients on the basis of whether they might be particularly 
vulnerable to the acquisition of advanced-stage and/or 
therapy-resistant disease.
RESULTS
Chromosomal changes in cancer cells
More than 100 years ago, Theodor Boveri speculated 
on the role of chromosome instability in cancer, based on 
his work in sea urchins. He reasoned that ‘a cancerous 
tumor begins with a single cell in which the makeup of 
its chromosomes becomes scrambled, causing the cells 
to divide uncontrollably’ [8]. It is now well established 
that cancer cells display two distinct types of karyotypic 
abnormalities. The first is a change in chromosome 
number (aneuploidy), and the second is a change in the 
structure of individual chromosomes caused by exchanges 
or rearrangements. These changes can be observed using 
conventional karyotyping (Figure 1), but are more evident 
when using a more advanced method such as spectral 
karyotyping (SKY), which employs fluorescently-
labeled probes to mark all of the DNA originating from 
a particular chromosome. It is known that about 85% of 
solid tumors show CIN in the form of aneuploidy, which 
is also the underlying cause of copy number changes of 
proto-oncogenes [9]. Indeed, we now know that many 
of the structural changes in individual chromosomes are 
directly responsible for the activation of oncogenes (via 
translocation or duplication) or inactivation of tumor 
suppressor genes (via deletion or mutation). 
Chromosome number changes
The chromosome number changes that are 
characteristic of cancers are frequently caused by the 
inaccurate segregation of chromosomes during mitosis. 
To ensure that an equal number of chromosomes are 
distributed to the two daughter cells, progression through 
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the key stages of mitosis is monitored by a series of 
checkpoints involving over 100 proteins. Thus far, four 
major changes have been described that can lead to 
the onset of chromosome number changes in tumors. 
The first is a defect in the spindle assembly checkpoint 
(SAC) caused by mutation or deregulation of any of 
several proteins, including BUB1B, MAD1L1, MAD2L1, 
and CENPE [10-12]. The second cause is a defect in 
microtubule attachment, with perhaps the most destructive 
form being so-called ‘merotely’, where one kinetochore 
becomes attached to microtubules from opposite spindle 
poles. Kinetochores are often observed to be merotelically 
attached to spindles in the early stages of mitosis, but 
this is generally corrected during metaphase [13, 14]. 
However, when aberrantly attached kinetochores persist 
until anaphase, sister chromatid missegregation usually 
results. The control of kinetochore-microtubule attachment 
is governed by an extensive network of different 
proteins, including PLK1, the Aurora A and B kinases, 
and cyclin-CDK complexes, which have been reported 
dysregulated in cancer cells (reviewed in [15]). A third 
cause for chromosome number changes is the existence 
of supernumerary centrosomes in mitotic cells, which 
can result either directly through a failure to suppress 
centriole over-duplication [16] or indirectly because of 
an aborted mitosis due to cytokinesis failure. The fourth 
major cause is via defects in the cohesin protein complex 
that holds sister chromatids together after DNA replication 
until anaphase. For example, loss of function mutations 
in STAG2, which encodes the cohesin protein complex 
subunit SA-2, has been found in cancer cell lines and in 
primary tumors [17]. Indeed, CIN can be induced in a 
karyotypically stable cell line following transfection of a 
mutated STAG2 cDNA [17]. Similarly, some CIN cell lines 
have defects in the recruitment of Shugoshin 1 protein 
(SGO1) that coordinates sister chromatid cohesion and 
kinetochore-microtubule attachment [18]. 
Figure 1: Representative karyotypes of a virally transformed lymphocyte from a normal individual (GM06865) (A), 
and of an osteosarcoma cell line (U2OS) with CIN (B). Unlike the diploid normal lymphocyte, the aneuploidy U2OS cell karyotype 
is highly abnormal with many chromosomes showing such an abnormal G-banding pattern that they could not be reliably assigned.
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Chromosome structural changes
Recent cancer genome sequencing efforts have 
revealed that a set of unstable regions of the genome 
called common fragile sites (CFSs) lead to recurrent 
chromosomal structural changes in cancers. This assertion 
is based on three observations: (i) Some oncogenes or 
tumor suppressor genes are encoded within CFS loci 
[19]; (ii) CFS sequences are frequently found at the 
breakpoints of cancer-specific DNA translocations [20-
24], and (iii) A significant proportion of the regions 
most frequently associated with focal deletions in cancer 
lie in CFS loci [25]. CFSs are chromosomal loci that 
tend to form a gap, break or constriction that is visible 
on condensed metaphase chromosomes. Despite their 
inherent instability, CFSs are evolutionally conserved 
chromosomal regions and, for example, generally map 
to syntenic regions of mouse and human chromosomes 
[26]. Moreover, they are present in all individuals. Their 
Figure 2: Representative IHC images of the expression of Ki-67, Cyclin E, POLD3, γH2AX, and FANCD2 in colon 
cancer FFPE specimens. 
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broken appearance (usually termed CFS ‘expression’) can 
be induced by exposing cells to agents that partially inhibit 
DNA synthesis, such as the DNA polymerase inhibitor 
aphidicolin (APH) [27]. To date, more than 200 CFSs have 
been identified in the human genome using this method 
[28]. 
Great advances have been made towards 
understanding the mechanism underlying CFS expression. 
The currently accepted model is that CFS expression 
reflects an inability to effect chromatin condensation 
due to a failure to complete DNA replication at the locus 
prior to mitotic entry [29, 30]. This, of course, begs the 
question as to why completion of DNA replication would 
ever be impaired in some regions of the human genome. 
To address this question, several research groups have 
sought to define the molecular events leading to CFS 
expression following replication perturbation. One 
revealing feature of CFSs is that they recruit several 
DNA repair and DNA damage response proteins during 
conditions of RS, including ATR [31], BRCA1 [32], 
CHK1 [33], FANCD2 [34], RAD51, and γH2AX [35]. 
In our laboratory, we have focused on the FANCD2 
protein, which serves as excellent surrogate marker of the 
location of CFSs undergoing RS, because it binds to CFS 
loci irrespective of whether the chromosome is broken 
or not in metaphase [36]. FANCD2 foci first associate 
with CFSs in late S/G2 and remain there through mitosis, 
ultimately segregating evenly with the sister chromatids 
in anaphase. Indeed, it is clear that under-replicated 
CFSs recruit multiple DNA repair proteins, including the 
DNA structure-selective endonuclease MUS81-EME1 
in early mitosis, and that this promotes CFS expression 
[37]. This discovery is consistent with the notion that the 
expression of CFSs is not an accidental event, but instead 
is a programmed and regulated process. Indeed, we have 
proposed that CFS expression is actually beneficial for the 
maintenance of genome stability, because it prevents much 
more hazardous events, such as irreversible chromosome 
missegregation [37]. 
It has also been demonstrated recently that FANCD2 
plays a direct role in CFS replication through an ability 
to promote the resolution of DNA:RNA hybrids [38]. 
Figure 3: Representative images of the cellular response to RS (induced by a low dose of hydroxyurea; HU) in U2OS 
cells, as determined by IF staining for γH2AX and FANCD2. A selected cell is defined by the yellow arrow, and is enlarged in 
the bottom panel. Scale bars are indicated.
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In the context of CFSs, R-loops likely form due to 
replication being impeded by the presence of ongoing 
transcription at the locus. This would likely be particularly 
problematic in cases of a head-on collision between the 
replication and transcription machineries. In this context, 
it is clear that several CFSs have an unusual genomic 
structure that often incorporates a very long gene [39, 
40]. Hence, transcription of the gene takes so long to 
complete (sometimes more than one entire cell cycle) 
that a collision between the transcription machinery and 
the replisome is inevitable at some point during S-phase. 
Considering that the FANCD2 protein is part of the so-
called Fanconi anemia pathway, inactivation of which 
is responsible for a debilitating disorder associated with 
a predisposition to various cancers, its association with 
CFSs provides another line of evidence to suggest that the 
proper replication of CFSs is crucial for the suppression 
of oncogenesis. 
Table 1: A summary of the expression of Ki-67, Cyclin E, POLD3, γH2AX, and FANCD2 in 32 FFPE specimens from 
colon, lung, breast, and stomach cancer patients by IHC analysis. 
Case 






stage Ki-67 Cyclin E POLD3 γH2AX FANCD2
1 F 50 Colon, Right-side Ulcerative type adenocarcinoma Moderate IIA ++ ++ ++ - ++
2 F 58 Colon, Right-side Ulcerative type adenocarcinoma Moderate IIA ++ ++ ++ - ++
3 F 68 Colon, Right-side  Ulcerative type adenocarcinoma Moderate IIA - ++ ++ ++ ++
4 F 69 Colon, Right-side Ulcerative type adenocarcinoma Moderate IIA - ++ ++ - -
5 M 28 Colon, Transverse+sigmoid  Ulcerative type adenocarcinoma Moderate IIIB + ++ ++ - ++
6 M 50 Colon, Rectum  Ulcerative type adenocarcinoma Moderate IIA + ++ ++ + ++
7 F 76 Colon, Right-side Ulcerative type adenocarcinoma Moderate IIA - ++ ++ - +
8 M 71 Colon, Sigmoid colon  Ulcerative type adenocarcinoma Moderate IIA ++ ++ ++ ++ +
9 F 76 Colon,Right-side Ulcerative type adenocarcinoma Moderate IIA + ++ ++ + ++
10 F 62 Colon,Ileocecus Ulcerative type adenocarcinoma Moderate IIIC ++ ++ ++ + -
11 M 51 Lung, superior lobe of right lung peripheral type 
squamous 
carcinoma Moderate IA ++ + ++ + +
12 M 66 Lung, superior lobe of left lung peripheral type 
squamous 
carcinoma Moderate IB ++ ++ + - +
13 M 51 Lung, superior lobe of right lung central type 
squamous 
carcinoma Moderate IIIA - + - - -
14 M 61 Lung, inferior lobe of right lung  central type 
squamous 
carcinoma Moderate IA ++ - ++ - ++
15 M 57 Lung, superior lobe of left lung peripheral type  
adenosquamous 
carcinoma Moderate IB - + ++ + -
16 M 68 Lung, superior lobe of right lung peripheral type  adenocarcinoma Moderate IA - - + + -
17 F 56 Lung, right lung peripheral type  adenocarcinoma Moderate IA - ++ - ++ +
18 M 52 Lung, superior lobe of left lung  central type 
squamous 
carcinoma Moderate-low IIB + ++ ++ + -




Moderate IA - + ++ - -
20 F 45 Breast, left side / infiltrating ductal carcinoma Moderate IIA - ++ ++ + -
21 F 46 Breast, left side / infiltrating ductal carcinoma Moderate IIA - + ++ - -
22 F 50 Breast, right side / infiltrating ductal carcinoma Moderate IA - + ++ - -
23 F 56 Breast, left side / infiltrating ductal carcinoma Moderate IIA - + + - ++
24 F 47 Breast, right side / introductal carcinoma Moderate 0 - + ++ - +
25 F 60 Breast, left side / infiltrating ductal carcinoma Moderate IA - + ++ - -
26 F 51 Breast, left side / infiltrating ductal carcinoma Moderate IIA - + + - -
27 F 36 Breast, right side / infiltrating ductal carcinoma Moderate IIIA ++ - ++ - +
28 F 56 Stomach, Ulcerative type Ulcerative type adenocarcinoma Moderate IIA - ++ ++ - -
29 M 47 Stomach Ulcerative type adenocarcinoma Moderate IB - + ++ + +
30 F 42 Stomach  Ulcerative type adenocarcinoma Moderate IIA - + ++ + ++
31 F 67 Stomach Ulcerative type adenocarcinoma Moderate IB - ++ ++ - +
32 M 63 Stomach Ulcerative type adenocarcinoma Moderate IB - ++ ++ + ++
F: female. M: male. ++: strong expression. +: moderate expression.  -: negative or very weak expression.
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Figure 4: A summary of the underlying mechanisms and detection of RS and CIN in cancer samples. Top panel: An 
illustration of increasing levels of RS and CIN during multi-step carcinogenesis using colorectal cancer as an example. During this process, 
multiple tumor suppressor genes (in green below the diagram) lose their function in the maintenance of genome stability, while multiple 
oncogenes (in red below the diagram) become activated and stimulate cells to proliferate. The RS and CIN thus formed become mutually 
reinforcing events that allow the cancer cells to ‘evolve’ and develop metastatic potential and drug resistance. Lower panel: A summary of 
the methods that can be applied to the detection of RS and CIN in laboratory or clinic settings. RS: replication stress. CIN: chromosome 
instability. UFB: ultra-fine anaphase DNA bridge. IF: immunofluorescence. IHC: Immunohistochemistry.
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Replication Stress in Cancer Cells
In the past decade, evidence has emerged for 
a positive correlation between tumorigenesis and 
the degree of RS [41-44]. This suggests that RS is a 
plausible candidate for being a valuable biomarker in 
solid tumors. It is therefore essential to obtain detailed 
knowledge on the events and proteins involved in dealing 
with this form of stress in human cells. It is clear that, 
at the molecular level, the RS associated with oncogene 
activation in cancers can be generated in several ways, 
such as by atypical DNA secondary structures, including 
hairpins or G-quadruplexes, a specific chromatin structure 
that impedes replication fork progression or a collision 
between the replisome and the transcription machinery 
operating on the same template. Exogenous stress factors 
can also generate RS, including several classes of DNA 
damaging agents, as well as drugs that cause depletion 
or imbalance of dNTPs (reviewed in [45]). Furthermore, 
factors required for replication fork stability, repair and 
restart in response to RS, such as the BRCA1 and BRCA2 
proteins, SLX4, and FA group members, have all been 
shown to associated with cancer development when their 
function is compromised in either human or mouse models 
(reviewed in [46]). This indicates that cancer cells have 
indeed developed various ways to cope with RS. 
In normal cells, the ATR-CHK1 kinase cascade is 
employed to cope with RS (reviewed in [47]. However, 
the detailed mechanism underlying how stalled replication 
forks are repaired and DNA synthesis is re-initiated is still 
largely unknown. Several models, which are not mutually 
exclusive, have been proposed to explain this process. 
These include the re-priming of DNA synthesis at a non-
origin site, the activation of dormant origins to rescue sites 
of slow replication, template switching, and homologous 
recombination-based processes such as break-induced 
replication (BIR). In cancer cells, there is evidence to 
show that an abnormal DNA damage response is more 
likely to be associated with advanced cancer stage, and 
chemotherapy resistance although the results remains 
controversial due to the different tissue type and genetic 
background of the samples analyzed [48-51]. Moreover, 
there is evidence to indicate that some of the pathways 
that might permit cells to resist persistent RS are highly 
activated; for example, the error prone TLS pathway 
[52, 53]. This suggests that the response to RS in cancer 
cells is deregulated in a more general way. This, in turn, 
could lead to CIN when cells containing under-replicated 
chromosomal regions (e.g. CFS regions) enter mitosis, 
because these regions have a tendency to missegregate 
in anaphase. Disturbances such as this in anaphase have 
the potential to drive chromosome nondisjunction or the 
formation of micronuclei in daughter cells. Interestingly, 
micronuclei are now recognized as a source of an extreme 
form of CIN called chromothripsis (a phenomenon by 
which multiple chromosomal rearrangements occur in 
a single event in localized genomic regions in one or a 
few chromosomes) that is increasingly being detected in 
cancer genomes.
Recently, we demonstrated that DNA synthesis can 
still be occurring at CFSs after the cell has entered mitosis, 
if the cells were treated with a low dose of APH in S phase 
[54]. We showed that entry into mitotic prophase triggers 
the recruitment of MUS81-EME1 to CFSs, and the 
nuclease activity of MUS81 then promotes a form of DNA 
synthesis that requires POLD3, a non-catalytic subunit of 
DNA Polymerase. POLD3 is the human ortholog of yeast 
Pol32, which plays a specialized role in certain forms of 
DNA repair in yeast, most notably BIR. Indeed, previous 
studies in human cells have proposed that POLD3 
functions in a BIR-like pathway that is responsible for 
creating segmental genomic duplications [55]. It is most 
likely that the POLD3-dependent DNA synthesis present 
in mitosis (which we termed MiDAS; [56]) serves as a 
‘rescue’ strategy in the cell to minimize chromosome 
missegregation and non-disjunction at CFSs in mitosis. 
Indeed, our data indicated that MiDAS play a particularly 
important role in the survival of cancer cells with CIN 
[54]. Very recently, we have demonstrated further that 
MiDAS often involves DNA synthesis taking place on a 
single sister chromatid, which is a hallmark of BIR [56]. 
Clearly, there is a need to define a set of markers 
that can indicate RS levels or the types of response to RS 
Table 2: Correlation analysis of the expression of Ki-67, Cyclin E, POLD3, γH2AX, and FANCD2 in 32 FFPE specimens 
from colon, lung, breast, and stomach cancer patients. 
Ki-67 Cyclin E POLD3 γH2AX FANCD2
Ki-67 1 0.34375 0.4375 0.5625 0.65625
Cyclin E 1 0.84375 0.46875 0.5625
POLD3 1 0.4375 0.59375
γH2AX 1 0.53125
FANCD2 1
The expression scores for each protein in each sample were classified into two categories: strong/moderate expression (++, 
or +) or absent/very weak expression (-). The two categories were then subjected to Jaccard similarity coefficient analysis for 
each protein. Jaccard index operates on a scale of 0–1, with the higher the score denoting cases where the expression pattern 
between the two proteins examined is more similar. The Protein names are in bold and the highest Jaccard index number is 
highlighted in bold.
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in cancer cells, which can be used for diagnosis, prognosis 
or for influencing therapeutic strategies for cancer. Despite 
the fact that inhibitors of the ATR and CHK1 kinases are 
undergoing clinical trials (reviewed in [57]), a biomarker 
for reliably indicating the level of RS is still not available 
for use in the clinic. The ideal biomarker assay for 
properly ‘staging’ a cancer patient should be sensitive, 
rapid, cost-effective, and robust against inter-operator 
and inter-institutional variability. In this regard, it has 
been proven very challenging to translate the information 
obtained from the laboratory to the ‘bedside’ (reviewed 
in [58]).
A pilot study of possible markers on RS response
Because RS is a common feature of most cancer 
cells, it is likely that RS exists in one form or another 
in a very wide range of cancer types. A corollary to this, 
therefore, is that the proteins involved in RS response 
pathways are strong candidates to be used as a biomarker 
of the degree of RS, malignant potential or response to 
treatment in many cancer types. As a first step in testing 
this hypothesis, we carried out a pilot study to analyze 
the expression of five proteins (Ki-67, Cyclin E, POLD3, 
γH2AX and FANCD2) on a collection of 32 tumor samples 
from a representative range of cancer types (colon, lung, 
breast or stomach). These samples were chosen also 
because they represent a similar pathology grade (Table 
1). The aim of this pilot study was to validate whether 
some of these markers are expressed in a consistent 
manner of tumors of similar histological grade regardless 
of their tissue origin or clinical stage. We optimized 
conditions for detection of the above proteins on paraffin-
embedded tissue sections using immunohistochemical 
(IHC) staining method, as most of these proteins have only 
been detected in cultured cells using immunofluorescence 
(Figure 2). Our results provide some expected and some 
very unexpected patterns of expression (Table 1). For 
example, the expression patterns of POLD3 and Cyclin E 
are strikingly similar in all of the samples (Table 2). These 
data correlate with the fact that POLD3 plays an important 
role in DNA replication and Cyclin E promotes S-phase 
entry. It might be expected, therefore, that the expression 
pattern of Cyclin E and POLD3 would correlate well with 
that of Ki-67, an established proliferation marker used 
in pathology studies worldwide. However, they did not. 
Another curious finding was that the expression of γH2AX 
and FANCD2 rarely correlated with each other, despite the 
fact that in vitro studies using cell lines have indicated that 
γH2AX and FANCD2 activation are associated with RS, 
and commonly used as surrogate markers of RS arising at 
CFSs (Figure 3). Moreover, POLD3 plays a key role in 
counteracting RS at CFSs, and yet its expression did not 
correlate with either that of γH2AX or FANCD2. Overall, 
therefore, it is clear that the widely used RS markers in cell 
line studies need very careful evaluation in clinical biopsy 
samples before being considered serious contenders as 
useful biomarkers. Finally, it is worth noting that there 
was no obvious difference in the expression pattern of the 
proteins tested in the samples from different tumor types, 
which is consistent with the notion that RS is a common 
feature of a wide range of cancer types. 
DISCUSSION
In recent years, there has been considerable progress 
in understanding the molecular events occurring during 
tumorigenesis. It is clear that abnormalities during DNA 
replication and the accompanying RS are common features 
of cancer cells. RS could be one of the most important 
drivers of genome instability, which in turn would 
permit cancer cells to develop phenotypic heterogeneity, 
such as an ability to metastasize or to acquire resistance 
to chemotherapy. Cancer cells have clearly evolved 
mechanisms to cope with persistent inherent RS. At the 
present time, we are in need a biomarker that can reliably 
detect RS in biopsies or reveal the cellular responses to RS 
that exist in cancers. Because of the routine use of cancer 
tissue pathology in clinics worldwide, it is important 
that these markers are robust enough to be studied using 
IHC based methods (Figure 4). Our pilot study indicates 
that it is possible to develop this kind of biomarker by 
testing various components in the RS pathways on both 
cancer cells in the laboratory and biopsies from cancer 
patients. Similar analysis should be performed in a larger 
collection of specimens with more comprehensive analysis 
relevant to the pathological and clinical characteristics of 
the tumors. Nevertheless, we hope this article, together 
with its pilot study, will facilitate future studies in this 
direction. The outcome of any biomarker analysis in 
the RS pathway would allow us to define whether the 
expression of proteins involved in the RS pathway could 
be a suitable predictor of the prognosis of patients treated 
with existing chemotherapy, or whether it could be used to 
stratify patients for treatment with one of the RS inhibitors 
that is being developed to target the RS pathway.
MATERIALS AND METHODS
Cell lines and culture conditions
Osteosarcoma cells (U2OS, obtained from ATCC) 
were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Thermo Fisher Scientific) supplemented with 
10% fetal bovine serum (FBS) and antibiotics. GM06865 
lymphocytes (obtained from Coriell Biorepository) were 
maintained in RPMI 1640 medium (Thermo Fisher 
Scientific) supplemented with 15% FBS and antibiotics. 
Both types of cells were cultured at 37°C in an atmosphere 
of 5% CO2. For replication stress analysis, asynchronously 
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growing cells were seeded onto glass coverslips (Sigma-
Aldrich) and were treated with 0.2 mM hydroxyurea (HU; 
Sigma-Aldrich) for 16 hours. For karyotype analysis, 
asynchronously growing cells were treated with 0.1 µg/
ml colcemid (Karyomax, Thermo Fisher Scientific) for 5 
hours before being harvested. 
Immunofluorescence (IF) analysis
Cells fixed on glass cover slips were blocked with 
3% BSA (Sigma-Aldrich) for 1 hour at room temperature 
and incubated with primary antibodies at 4°C overnight, 
followed by three washes (30 minutes each) using PBST 
(PBS with 0.2% Triton-X 100, Sigma-Aldrich). Slides 
were then incubated with secondary antibodies for 1 
hour at room temperature, followed by three washes 
(30 minutes each) using PBST. Air-dried coverslips 
were mounted using Vectashield mounting medium with 
DAPI (Vector Laboratories), and were analyzed with 
a Retiga6000 camera connected to an Olympus BX63 
microscope. The origins and dilutions of primary and 
secondary antibodies were: anti-FANCD2 (1:400, NB100-
182; Novus), anti-γH2AX (1:400, JBW-301; Millipore), 
Alexa Fluor 568 goat anti-rabbit IgG (1:500, A-1101; 
Invitrogen) and Alexa Fluor 488 goat anti-mouse IgG 
(1:500, A-110291; Invitrogen). 
Karyotype analysis
The karyotype of metaphase cells was obtained 
by standard G-banding and analyzed using a Leica light 
microscope equipped with CytoVision software.
Clinical specimens
Archival blocks of formalin-fixed, paraffin-
embedded (FFPE) tumor, neoplasia or normal specimens 
from the colon (n=13), lung (n=8), breast (n=9), or 
stomach (n=5) were obtained in accordance with local 
Research Ethics guidelines. All of the specimens were 
chosen according to their histological classification and 
the degree of cell differentiation. Information concerning 
the tumor specimens chosen for immunohistochemical 
(IHC) staining is shown in Table 1. 
IHC staining and evaluation
Sections (5 µm) were cut onto 
aminopropyltriethoxysilane (APES)-coated slides from 
each specimen. In each case, one of the sections was 
subjected to standard hematoxylin and eosin (H&E) 
staining to confirm histological diagnosis, while 
the rest were subjected to IHC analysis using a SP-
9000, SPlink Detection Kit following manufacturer’s 
instructions (Zhong Shan -Golden Bridge Biological 
Technology Co. Ltd., Beijing, China). The origins and 
the dilutions of the primary antibodies used are: anti-
gamma H2AX (polyclonal, Abcam, ab2893, 1:400), 
anti-POLD3(monoclonal, Abcam, ab182564, 1:70), anti-
FANCD2 (monoclonal, Abcam, ab108928, 1:80), anti-
CyclinE (polyclonal, BIOSS, Bs-8929R, 1:150), and anti-
Ki67 (monoclonal, Gene Tex, GTX83375, 1:400). All of 
the primary antibodies were incubated with pre-blocked 
slides at 4 °C overnight. The secondary antibodies were 
goat anti-mouse or goat anti-rabbit HRP for 30 minutes. 
3,3’-diaminobenzidine (DAB) was used as the chromogen. 
Negative controls were preformed by omitting the primary 
antibody. The images were captured using an Olympus 
DP73 camera connected to an Olympus BX53 microscope. 
Staining results were assessed independently by three 
pathologists on coded samples.
The expression level of the protein analyzed was 
scored as described in [59]. In brief, the intensity of IHC 
staining was scored from 0 to 4 as: 0, negative; 1, weak; 
2, moderate; and 3, strong. The proportion of the cells 
stained positively was scored from 0 to 4 as: 0, less than 
5%; 1, 5-25%; 2, 26-50%; 3, 51-75; and 4, over 76%. A 
final ‘expression score’ for each antibody in each specimen 
was achieved by multiplying the scores of intensity and 
proportion of the positive cells. Scores of 9-12 were 
defined as “strong expression”, scores of 5-8 were defined 
as “reduced expression”, and scores of 0-4 were defined as 
“negative or markedly reduced expression”. 
Author contributions
L.R., L.C., W.W., L.G., H.T., and Z.L. carried out 
experiments. I.V. performed data analysis. L.R., C.L., 
I.D.H. and Y.L. designed experiments and interpreted 
results. I.D.H. and Y.L. wrote the manuscript, and all 
authors edited it. 
ACKNOWLEDGMENTS
We thank all members in Liu and Hickson groups 
for helpful discussions. We apologize to the authors whose 
work is not cited due to space restrictions. 
CONFLICTS OF INTEREST
The authors have declared that no conflict of interest 
exists. 
FUNDING
The work in the authors’ laboratory is supported 
by The Department Of Science And Technology of 
Hebei province, China (169A76220H) (L.R.), Chinese 
Scholarship Council (W.W.), European Union (I.D.H., and 
Oncotarget37006www.impactjournals.com/oncotarget
Y.L.), The Danish National Research Foundation (I.D.H. 
and Y.L.), and The Nordea Foundation (I.D.H.). 
REFERENCES
1. WHO. Cancer fact sheets: All cancers excluding non-
melanoma skin. http://gco.iarc.fr/today/fact-sheets-
cancers?cancer=29&type=0&sex=0, 2013.
2. NIH. Cancer Stat Facts: Colon and Rectum Cancer. https://
seer.cancer.gov/statfacts/html/colorect.html, 2016.
3. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary 
RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo 
S, Dezso Z, et al. The genomic landscapes of human breast 
and colorectal cancers. Science. 2007; 318:1108-1113.
4. Lecona E, Fernandez-Capetillo O. Replication stress and 
cancer: it takes two to tango. Exp Cell Res. 2014; 329:26-
34.
5. Hills SA, Diffley JF. DNA replication and oncogene-
induced replicative stress. Curr Biol. 2014; 24:R435-444.
6. Sansregret L, Swanton C. The Role of Aneuploidy in 
Cancer Evolution. Cold Spring Harb Perspect Med. 2017; 7.
7. Burrell RA, McClelland SE, Endesfelder D, Groth P, 
Weller MC, Shaikh N, Domingo E, Kanu N, Dewhurst 
SM, Gronroos E, Chew SK, Rowan AJ, Schenk A, et al. 
Replication stress links structural and numerical cancer 
chromosomal instability. Nature. 2013; 494:492-496.
8. Harris H. Concerning the origin of malignant tumours by 
Theodor Boveri. Translated and annotated by Henry Harris. 
J Cell Sci. 2008; 121: v-vi.
9. Rajagopalan H, Lengauer C. Aneuploidy and cancer. 
Nature. 2004; 432:338-341.
10. Hanks S, Coleman K, Reid S, Plaja A, Firth H, Fitzpatrick 
D, Kidd A, Mehes K, Nash R, Robin N, Shannon N, Tolmie 
J, Swansbury J, et al. Constitutional aneuploidy and cancer 
predisposition caused by biallelic mutations in BUB1B. Nat 
Genet. 2004; 36:1159-1161.
11. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos 
M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, 
Lowe SW, Cordon-Cardo C. Rb inactivation promotes 
genomic instability by uncoupling cell cycle progression 
from mitotic control. Nature. 2004; 430:797-802.
12. Putkey FR, Cramer T, Morphew MK, Silk AD, Johnson 
RS, McIntosh JR, Cleveland DW. Unstable kinetochore-
microtubule capture and chromosomal instability following 
deletion of CENP-E. Dev Cell. 2002; 3:351-365.
13. Cimini D, Cameron LA, Salmon ED. Anaphase spindle 
mechanics prevent mis-segregation of merotelically 
oriented chromosomes. Curr Biol. 2004; 14:2149-2155.
14. Cimini D, Moree B, Canman JC, Salmon ED. Merotelic 
kinetochore orientation occurs frequently during early 
mitosis in mammalian tissue cells and error correction is 
achieved by two different mechanisms. J Cell Sci. 2003; 
116:4213-4225.
15. Godek KM, Kabeche L, Compton DA. Regulation of 
kinetochore-microtubule attachments through homeostatic 
control during mitosis. Nat Rev Mol Cell Biol. 2015; 16:57-
64.
16. Nigg EA, Stearns T. The centrosome cycle: Centriole 
biogenesis, duplication and inherent asymmetries. Nature 
cell biology. 2011; 13:1154-1160.
17. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun 
AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, 
Ladanyi M, Samuels Y, James CD, Yu H, et al. Mutational 
inactivation of STAG2 causes aneuploidy in human cancer. 
Science. 2011; 333:1039-1043.
18. Tanno Y, Susumu H, Kawamura M, Sugimura H, Honda 
T, Watanabe Y. The inner centromere-shugoshin network 
prevents chromosomal instability. Science. 2015; 349:1237-
1240.
19. Richards RI. Fragile and unstable chromosomes in cancer: 
causes and consequences. Trends in genetics. 2001; 17:339-
345.
20. Arlt MF, Durkin SG, Ragland RL, Glover TW. Common 
fragile sites as targets for chromosome rearrangements. 
DNA Repair. 2006; 5:1126-1135.
21. Balci A, Ekmekc A, Cetin R. The expression of common 
fragile sites in peripheral blood lymphocytes of breast and 
colorectal cancer patients with aphidicolin. Tohoku J Exp 
Med. 1999; 189:107-116.
22. Bouffler S, Silver A, Papworth D, Coates J, Cox R. Murine 
Radiation Myeloid Leukemogenesis - Relationship between 
Interstitial Telomere-Like Sequences and Chromosome-2 
Fragile Sites. Gene Chromosome Canc. 1993; 6:98-106.
23. Finnon R, Moody J, Meijne E, Haines J, Clark D, Edwards 
A, Cox R, Silver A. A major breakpoint cluster domain in 
murine radiation-induced acute myeloid leukemia. Mol 
Carcinogen. 2002; 34:64-71.
24. Gumus G, Sunguroglu A, Tukun A, Sayin DB, Bokesoy 
I. Common fragile sites associated with the breakpoints 
of chromosomal aberrations in hematologic neoplasms. 
Cancer Genet Cytogen. 2002; 133:168-171.
25. Savelyeva L, Brueckner LM. Molecular characterization 
of common fragile sites as a strategy to discover cancer 
susceptibility genes. Cell Mol Life Sci. 2014; 71:4561-
4575.
26. Helmrich A, Stout-Weider K, Hermann K, Schrock E, 
Heiden T. Common fragile sites are conserved features of 
human and mouse chromosomes and relate to large active 
genes. Genome Res. 2006; 16:1222-1230.
27. Durkin SG, Glover TW. Chromosome fragile sites. Annual 
review of genetics. 2007; 41:169-192.
28. Mrasek K, Schoder C, Teichmann AC, Behr K, Franze 
B, Wilhelm K, Blaurock N, Claussen U, Liehr T, Weise 
A. Global screening and extended nomenclature for 
230 aphidicolin-inducible fragile sites, including 61 yet 
unreported ones. International journal of oncology. 2010; 
36:929-940.
29. Sutherland GR. Rare fragile sites. Cytogenetic and genome 
Oncotarget37007www.impactjournals.com/oncotarget
research. 2003; 100:77-84.
30. El Achkar E, Gerbault-Seureau M, Muleris M, Dutrillaux B, 
Debatisse M. Premature condensation induces breaks at the 
interface of early and late replicating chromosome bands 
bearing common fragile sites. Proc Natl Acad Sci U S A. 
2005; 102:18069-18074.
31. Casper AM, Nghiem P, Arlt MF, Glover TW. ATR 
regulates fragile site stability. Cell. 2002; 111:779-789.
32. Arlt MF, Xu B, Durkin SG, Casper AM, Kastan MB, 
Glover TW. BRCA1 is required for common-fragile-site 
stability via its G2/M checkpoint function. Mol Cell Biol. 
2004; 24:6701-6709.
33. Durkin SG, Arlt MF, Howlett NG, Glover TW. Depletion of 
CHK1, but not CHK2, induces chromosomal instability and 
breaks at common fragile sites. Oncogene. 2006; 25:4381-
4388.
34. Howlett NG, Taniguchi T, Durkin SG, D’Andrea AD, 
Glover TW. The Fanconi anemia pathway is required for 
the DNA replication stress response and for the regulation 
of common fragile site stability. Human molecular genetics. 
2005; 14:693-701.
35. Schwartz M, Zlotorynski E, Goldberg M, Ozeri E, Rahat 
A, le Sage C, Chen BPC, Chen DJ, Agami R, Kerem B. 
Homologous recombination and nonhomologous end-
joining repair pathways regulate fragile site stability. Genes 
& development. 2005; 19:2715-2726.
36. Chan KL, Palmai-Pallag T, Ying SM, Hickson ID. 
Replication stress induces sister-chromatid bridging at 
fragile site loci in mitosis. Nature cell biology. 2009; 
11:753-U120.
37. Ying SM, Minocherhomji S, Chan KL, Palmai-Pallag T, 
Chu WK, Wass T, Mankouri HW, Liu Y, Hickson ID. 
MUS81 promotes common fragile site expression. Nature 
cell biology. 2013; 15:1001-1007.
38. Madireddy A, Kosiyatrakul ST, Boisvert RA, Herrera-
Moyano E, Garcia-Rubio ML, Gerhardt J, Vuono EA, 
Owen N, Yan Z, Olson S, Aguilera A, Howlett NG, 
Schildkraut CL. FANCD2 Facilitates Replication through 
Common Fragile Sites. Molecular cell. 2016; 64:388-404.
39. Le Tallec B, Millot GA, Blin ME, Brison O, Dutrillaux B, 
Debatisse M. Common Fragile Site Profiling in Epithelial 
and Erythroid Cells Reveals that Most Recurrent Cancer 
Deletions Lie in Fragile Sites Hosting Large Genes. Cell 
Rep. 2013; 4:420-428.
40. Wilson TE, Arlt MF, Park SH, Rajendran S, Paulsen M, 
Ljungman M, Glover TW. Large transcription units unify 
copy number variants and common fragile sites arising 
under replication stress. Genome Res. 2015; 25:189-200.
41. Barlow JH, Faryabi RB, Callen E, Wong N, Malhowski A, 
Chen HT, Gutierrez-Cruz G, Sun HW, McKinnon P, Wright 
G, Casellas R, Robbiani DF, Staudt L, et al. Identification 
of early replicating fragile sites that contribute to genome 
instability. Cell. 2013; 152:620-632.
42. Blumrich A, Zapatka M, Brueckner LM, Zheglo D, Schwab 
M, Savelyeva L. The FRA2C common fragile site maps to 
the borders of MYCN amplicons in neuroblastoma and 
is associated with gross chromosomal rearrangements 
in different cancers. Human molecular genetics. 2011; 
20:1488-1501.
43. Pelliccia F, Bosco N, Rocchi A. Breakages at common 
fragile sites set boundaries of amplified regions in two 
leukemia cell lines K562 - Molecular characterization of 
FRA2H and localization of a new CFS FRA2S. Cancer Lett. 
2010; 299:37-44.
44. Tomasetti C, Vogelstein B. Cancer etiology. Variation in 
cancer risk among tissues can be explained by the number 
of stem cell divisions. Science. 2015; 347:78-81.
45. Munoz S, Mendez J. DNA replication stress: from 
molecular mechanisms to human disease. Chromosoma. 
2016; 126:1-15.
46. Gaillard H, Garcia-Muse T, Aguilera A. Replication stress 
and cancer. Nat Rev Cancer. 2015; 15:276-289.
47. Cimprich KA, Cortez D. ATR: an essential regulator of 
genome integrity. Nat Rev Mol Cell Biol. 2008; 9:616-627.
48. Bi J, Huang A, Liu T, Zhang T, Ma H. Expression of DNA 
damage checkpoint 53BP1 is correlated with prognosis, cell 
proliferation and apoptosis in colorectal cancer. Int J Clin 
Exp Pathol. 2015; 8:6070-6082.
49. Neboori HJ, Haffty BG, Wu H, Yang Q, Aly A, Goyal 
S, Schiff D, Moran MS, Golhar R, Chen C, Moore D, 
Ganesan S. Low p53 binding protein 1 (53BP1) expression 
is associated with increased local recurrence in breast 
cancer patients treated with breast-conserving surgery and 
radiotherapy. Int J Radiat Oncol Biol Phys. 2012; 83:e677-
683.
50. Pennington KP, Wickramanayake A, Norquist BM, Pennil 
CC, Garcia RL, Agnew KJ, Taniguchi T, Welcsh P, Swisher 
EM. 53BP1 expression in sporadic and inherited ovarian 
carcinoma: Relationship to genetic status and clinical 
outcomes. Gynecol Oncol. 2013; 128:493-499.
51. Takeyama K, Monti S, Manis JP, Dal Cin P, Getz G, 
Beroukhim R, Dutt S, Aster JC, Alt FW, Golub TR, Shipp 
MA. Integrative analysis reveals 53BP1 copy loss and 
decreased expression in a subset of human diffuse large 
B-cell lymphomas. Oncogene. 2008; 27:318-322.
52. Albertella MR, Lau A, O’Connor MJ. The overexpression 
of specialized DNA polymerases in cancer. DNA Repair 
(Amst). 2005; 4:583-593.
53. Shi TY, Yang L, Yang G, Tu XY, Wu X, Cheng X, Wei 
Q. DNA polymerase zeta as a potential biomarker of 
chemoradiation resistance and poor prognosis for cervical 
cancer. Med Oncol. 2013; 30:500.
54. Minocherhomji S, Ying S, Bjerregaard VA, Bursomanno 
S, Aleliunaite A, Wu W, Mankouri HW, Shen H, Liu 
Y, Hickson ID. Replication stress activates DNA repair 
synthesis in mitosis. Nature. 2015; 528:286-290.
55. Costantino L, Sotiriou SK, Rantala JK, Magin S, Mladenov 
E, Helleday T, Haber JE, Iliakis G, Kallioniemi OP, 
Oncotarget37008www.impactjournals.com/oncotarget
Halazonetis TD. Break-induced replication repair of 
damaged forks induces genomic duplications in human 
cells. Science. 2014; 343:88-91.
56. Bhowmick R, Minocherhomji S, Hickson ID. RAD52 
Facilitates Mitotic DNA Synthesis Following Replication 
Stress. Molecular cell. 2016; 64:1117-1126.
57. Dobbelstein M, Sorensen CS. Exploiting replicative stress 
to treat cancer. Nat Rev Drug Discov. 2015; 14:405-423.
58. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, 
prognosis and treatment selection. Nat Rev Cancer. 2005; 
5:845-856.
59. Hao XP, Pretlow TG, Rao JS, Pretlow TP. Beta-catenin 
expression is altered in human colonic aberrant crypt foci. 
Cancer Res. 2001; 61:8085-8088.
